But early trials noted something else: patients were losing weight not from nausea alone, but from true reductions in appetite and caloric intake
Using a questionnaire, Kuwasawa-Iwasaki M et al
"FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight." The drug, semaglutide, known commercially as Wegovy, was previously approved for FDA use at a lower dose for Type 2 diabetes treatment
The geography and commercial context of the research Much of the skin-lightening research on glutathione originates in regions where lighter skin carries strong cultural and commercial value notably the Philippines, Thailand, India, and parts of East Asia
Pfiffner, M., Brown, W., & Jayaraman, S